the secretagogue that also made people hungry
1977 (initial observation) – 1984 (GHRP-6 characterized and published)
Bowers spent roughly fifteen years insisting his lab-made peptide had to be mimicking a real hormone nobody had found yet — and in 1999 a Japanese team pulled that hormone out of ground-up rat stomachs and named it "ghrelin," after the Proto-Indo-European root for "grow."
In the late 1970s, endocrinologist Cyril Y. Bowers at Tulane University wasn't chasing a growth-hormone drug at all — he was studying enkephalins, the brain's own opioid-like painkillers, dripping chemically tweaked versions onto cultured pituitary cells. Then something happened the opioid textbooks gave him no reason to expect: certain enkephalin-amide analogs, stripped of any painkilling punch, made the cells start dumping growth hormone. A side-effect of opioid-receptor tinkering had accidentally exposed an entirely separate signaling pathway nobody had described.
Rather than toss the stray result, Bowers teamed up with chemist Frank Momany to deliberately optimize it, screening batch after batch of small peptide variants. The work landed in two companion 1984 papers in Endocrinology, describing a synthetic six-amino-acid chain — His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 — that released growth hormone through a mechanism clearly distinct from GHRH, the hypothalamic hormone everyone assumed was the only legitimate trigger. This was GHRP-6, and it founded an entire dynasty: GHRP-1, GHRP-2, hexarelin, and eventually ipamorelin all descend from it.
Then came the genuinely strange part: for roughly fifteen years, Bowers publicly argued that a peptide his own lab had built from scratch couldn't be hitting a receptor that existed only to bind a made-up drug — somewhere, the body had to be making a natural version he was accidentally imitating. Most of the field wasn't buying it. But in 1996 Howard and colleagues cloned the actual receptor, GHS-R1a, as an 'orphan' with no known biological partner — and in 1999 Masayasu Kojima, Kenji Kangawa and their team in Japan used that orphan to fish through ground-up rat stomachs and reeled in a 28-amino-acid peptide that switched it on. They named it ghrelin, after 'ghre,' the Proto-Indo-European root for 'grow' — and a vindicated Bowers later wrote up the whole arc under the perfect title 'Unnatural GHRP Begets Natural Ghrelin.'
The appetite twist followed the same 'nuisance becomes the point' pattern. GHRP-6 was built purely as a GH-releaser, yet researchers and later users kept noticing it also switched on fast, powerful hunger. Once ghrelin biology clicked into place the reason was obvious: GHS-R1a is ghrelin's receptor, and ghrelin is the gut's primary hunger signal, so GHRP-6 was simply doing its natural counterpart's other job. That reframing is exactly what turned an 'annoying off-target effect' into a legitimate reason to study the whole ghrelin-receptor class for appetite loss and wasting conditions.
The backbone of this story holds up against independent academic sources, not just vendor blogs — the 1984 GHRP-6 papers, the 1996 receptor cloning, the 1999 ghrelin discovery, and Bowers's own 2001 retrospective are all in the peer-reviewed record. The only thing we trimmed: popular retellings stretch Bowers's "there must be a natural hormone" campaign to "over two decades," but the well-supported span from GHRP-6's 1984 debut to ghrelin's 1999 discovery is closer to fifteen years.
GHRP-6 itself never became an approved drug — as of 2026 it has no cleared clinical use anywhere and lives on as a "research chemical" sold to labs and, off-label and unofficially, to bodybuilding and anti-aging circles chasing its GH-releasing and appetite-boosting effects (it also sits on WADA's banned list for sport). Its real legacy is inherited: the ghrelin/GHS-R1a system it accidentally uncovered went on to yield genuine medicines — most notably <b>macimorelin</b> (FDA-approved in December 2017 as an oral test for adult growth-hormone deficiency) and <b>anamorelin</b> (approved in Japan in 2020 for cancer-related cachexia). GHRP-6 stays a lab tool and grey-market compound, but the biology it revealed is now real, prescribable pharmacology.
